<VariationArchive VariationID="684406" VariationName="NM_000404.4(GLB1):c.495_497del (p.Leu166del)" VariationType="Deletion" Accession="VCV000684406" Version="8" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-03-05" DateCreated="2019-08-31" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="672002" VariationID="684406">
      <GeneList>
        <Gene Symbol="GLB1" FullName="galactosidase beta 1" GeneID="2720" HGNC_ID="HGNC:4298" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>3p22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="32961108" stop="33097146" display_start="32961108" display_stop="33097146" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="33038099" stop="33138693" display_start="33038099" display_stop="33138693" Strand="-" />
          </Location>
          <OMIM>611458</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000404.4(GLB1):c.495_497del (p.Leu166del)</Name>
      <CanonicalSPDI>NC_000003.12:33065517:AGAAG:AG</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>3p22.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="33065518" stop="33065520" display_start="33065518" display_stop="33065520" variantLength="3" positionVCF="33065517" referenceAlleleVCF="CAGA" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="33107010" stop="33107012" display_start="33107010" display_stop="33107012" variantLength="3" positionVCF="33107009" referenceAlleleVCF="CAGA" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>L136del</ProteinChange>
      <ProteinChange>L166del</ProteinChange>
      <ProteinChange>L214del</ProteinChange>
      <ProteinChange>S95del</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000404.4" sequenceAccession="NM_000404" sequenceVersion="4" change="c.495_497delTCT" MANESelect="true">
            <Expression>NM_000404.4:c.495_497delTCT</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.33107012_33107014del" Assembly="GRCh37">
            <Expression>NC_000003.11:g.33107012_33107014del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.12" sequenceAccession="NC_000003" sequenceVersion="12" change="g.33065520_33065522del" Assembly="GRCh38">
            <Expression>NC_000003.12:g.33065520_33065522del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009005.1" sequenceAccession="NG_009005" sequenceVersion="1" change="g.36683_36685del">
            <Expression>NG_009005.1:g.36683_36685del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000404.4" sequenceAccession="NM_000404" sequenceVersion="4" change="c.495_497del" MANESelect="true">
            <Expression>NM_000404.4:c.495_497del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000395.3" sequenceAccession="NP_000395" sequenceVersion="3" change="p.Leu166del">
            <Expression>NP_000395.3:p.Leu166del</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001822" Type="inframe_deletion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001079811.3" sequenceAccession="NM_001079811" sequenceVersion="3" change="c.405_407del">
            <Expression>NM_001079811.3:c.405_407del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001073279.2" sequenceAccession="NP_001073279" sequenceVersion="2" change="p.Leu136del">
            <Expression>NP_001073279.2:p.Leu136del</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001822" Type="inframe_deletion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001135602.3" sequenceAccession="NM_001135602" sequenceVersion="3" change="c.283_285del">
            <Expression>NM_001135602.3:c.283_285del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001129074.2" sequenceAccession="NP_001129074" sequenceVersion="2" change="p.Ser95del">
            <Expression>NP_001129074.2:p.Ser95del</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001822" Type="inframe_deletion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001317040.2" sequenceAccession="NM_001317040" sequenceVersion="2" change="c.639_641del">
            <Expression>NM_001317040.2:c.639_641del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001303969.2" sequenceAccession="NP_001303969" sequenceVersion="2" change="p.Leu214del">
            <Expression>NP_001303969.2:p.Leu214del</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001822" Type="inframe_deletion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001393580.1" sequenceAccession="NM_001393580" sequenceVersion="1" change="c.495_497del">
            <Expression>NM_001393580.1:c.495_497del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001380509.1" sequenceAccession="NP_001380509" sequenceVersion="1" change="p.Leu166del">
            <Expression>NP_001380509.1:p.Leu166del</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001822" Type="inframe_deletion" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="754077128" DB="dbSNP" />
      </XRefList>
      <FunctionalConsequence Value="Unknown function" />
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000404.4(GLB1):c.495_497del (p.Leu166del) AND GM1 gangliosidosis type 2" Accession="RCV000844877" Version="1">
        <ClassifiedConditionList TraitSetID="245">
          <ClassifiedCondition DB="MedGen" ID="C0268272">GM1 gangliosidosis type 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-05-07" SubmissionCount="1">Uncertain significance</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.495_497del (p.Leu166del) AND multiple conditions" Accession="RCV001214281" Version="4">
        <ClassifiedConditionList TraitSetID="10013">
          <ClassifiedCondition DB="MedGen" ID="C0085131">GM1 gangliosidosis</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0086652">Mucopolysaccharidosis, MPS-IV-B</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-01-24" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.495_497del (p.Leu166del) AND Infantile GM1 gangliosidosis" Accession="RCV001585790" Version="2">
        <ClassifiedConditionList TraitSetID="244">
          <ClassifiedCondition DB="MedGen" ID="C0268271">Infantile GM1 gangliosidosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no classification provided</ReviewStatus>
            <Description SubmissionCount="1">not provided</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-01-24" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2019-08-31" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, conflicting classifications</ReviewStatus>
        <Description>Conflicting classifications of pathogenicity</Description>
        <Explanation DataSource="ClinVar" Type="public">Pathogenic(1); Uncertain significance(1)</Explanation>
        <Citation Type="general">
          <ID Source="PubMed">20920281</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30267299</ID>
        </Citation>
        <Comment DataSource="ClinVar" Type="public">Pathogenic(1); Uncertain significance(1)</Comment>
        <DescriptionHistory Dated="2020-07-15">
          <Description>Uncertain significance</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="10013" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="7352" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Beta galactosidase 1 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLB 1 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">GM1 gangliosidosis</ElementValue>
                <XRef ID="MONDO:0018149" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10891" />
                <XRef ID="10891" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="C0085131" DB="MedGen" />
              <XRef ID="MONDO:0018149" DB="MONDO" />
            </Trait>
            <Trait ID="2965" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">MPS IVB</ElementValue>
                <XRef Type="MIM" ID="253010" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Morquio syndrome B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type IV B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-IV-B</ElementValue>
                <XRef ID="Morquio+syndrome+B/4877" DB="Genetic Alliance" />
                <XRef ID="238044004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type 4B</ElementValue>
                <XRef ID="MONDO:0009660" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS 4B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type IVB (Morquio)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis Type IVB</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MPS4B</ElementValue>
                <XRef Type="MIM" ID="253010" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3786" />
                <XRef ID="3786" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="309310" DB="Orphanet" />
              <XRef ID="582" DB="Orphanet" />
              <XRef ID="C0086652" DB="MedGen" />
              <XRef ID="MONDO:0009660" DB="MONDO" />
              <XRef Type="MIM" ID="253010" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="244" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="5204" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">GM1-gangliosidosis, type I</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, generalized GM1, infantile form</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLB1 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, Generalized GM1, Type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1 gangliosidosis type 1</ElementValue>
                <XRef ID="MONDO:0009260" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Infantile GM1 gangliosidosis</ElementValue>
                <XRef ID="238026007" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6479" />
                <XRef ID="6479" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="79255" DB="Orphanet" />
              <XRef ID="C0268271" DB="MedGen" />
              <XRef ID="MONDO:0009260" DB="MONDO" />
              <XRef Type="MIM" ID="230500" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="245" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1390" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">GM1 gangliosidosis type 2</ElementValue>
                <XRef ID="MONDO:0009261" DB="MONDO" />
                <XRef ID="79256" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1-GANGLIOSIDOSIS, TYPE II</ElementValue>
                <XRef Type="MIM" ID="230600" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0022" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0003" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GANGLIOSIDOSIS, GENERALIZED GM1, TYPE II</ElementValue>
                <XRef Type="MIM" ID="230600" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, Generalized GM1, Type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Juvenile GM&gt;1&lt; gangliosidosis</ElementValue>
                <XRef ID="18756002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, generalized GM1, juvenile type</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">GLB1-Related Disorders</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10126" />
                <XRef ID="10126" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="79256" DB="Orphanet" />
              <XRef ID="C0268272" DB="MedGen" />
              <XRef ID="MONDO:0009261" DB="MONDO" />
              <XRef Type="MIM" ID="230600" DB="OMIM" />
              <Comment DataSource="NCBI curation" Type="public">REVIEWED: Set the orphanet value to preferred to avoid the annotation for the subscript</Comment>
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1934353" SubmissionDate="2019-08-06" DateLastUpdated="2019-08-31" DateCreated="2019-08-31">
        <ClinVarSubmissionID localKey="SUB5931802" submittedAssembly="GRCh37" title="SUB5931802" />
        <ClinVarAccession Accession="SCV000926257" DateUpdated="2019-08-31" DateCreated="2019-08-31" Type="SCV" Version="1" SubmitterName="Foundation for Research in Genetics and Endocrinology, FRIGE's Institute of Human Genetics" OrgID="505565" OrganizationCategory="other" OrgAbbreviation="FRIGE - IHG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-05-07">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Uncertain significance</GermlineClassification>
          <Comment>Heterozygous variant c.495_497del (p.Leu166del) in exon-5 has been observed in GLB1 gene. The proband, born of a non-consanguineous marriage, presented with clinical indication of regression of milestones, moderate mental retardation, seizures, hypotonia and myoclonal jerks. MRI was suggestive of cerebral atrophy. The patient in our clinical analysis was diagnosed with the said variant in an autosomal recessive mode of inheritance. The variant is not reported in the 1000 genomes and ExAC databases. In silico prediction of the variant is probably damaging by PolyPhen-2 (HumDiv) and damaging by SIFT, LRT and MutationTaster2. In summary, the said variant meets our criteria to be classified as uncertain significance based on the mode of inheritance, in silico prediction, allele frequency in population databases and lack of segregation study.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation Type="general">
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Indian Hindu</Ethnicity>
              <GeographicOrigin>India</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">0</Age>
              <Age Type="maximum" age_unit="years">9</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
              <Indication Type="Indication">
                <Trait Type="Finding">
                  <Name>
                    <ElementValue Type="Preferred">Clinical features observed in this individual</ElementValue>
                  </Name>
                </Trait>
              </Indication>
            </Sample>
            <Method>
              <NamePlatform>Illumina Sequencing Platform</NamePlatform>
              <TypePlatform>Next-generation sequencing</TypePlatform>
              <Description>DNA was used to perform targeted gene sequencing using a custom capture kit. Libraries were sequenced to mean &gt;80-100X coverage in Illumina sequencing platform. Sequence obtained were aligned to a human reference genome using BWA program and analyzed using Picard and GATK-Lite toolkit to identify variants in the targeted genes relevant to clinical indication.</Description>
              <MethodType>clinical testing</MethodType>
              <ObsMethodAttribute>
                <Attribute Type="TestingLaboratory" dateValue="2019-05-07">Foundation for Research in Genetics and Endocrinology</Attribute>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="1" />
            </ObservedData>
            <TraitSet DateLastEvaluated="2019-03-18" Type="Finding">
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0001249" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0001250" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0001290" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0001336" />
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1">
              <Name>galactosidase beta 1</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000404.4:exon 5</GeneLocation>
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">D-4551</Name>
            <Name>p.Leu166del</Name>
          </OtherNameList>
          <FunctionalConsequence Value="Unknown function" />
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.4:c.495_497del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230600" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5931802</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3562296" SubmissionDate="2021-09-01" DateLastUpdated="2022-10-01" DateCreated="2021-09-08">
        <ClinVarSubmissionID localKey="NM_000404.4:c.495_497delTCT|OMIM:230500" submittedAssembly="not applicable" />
        <ClinVarAccession Accession="SCV001821207" DateUpdated="2022-10-01" DateCreated="2021-09-08" Type="SCV" Version="2" SubmitterName="GeneReviews" OrgID="500062" OrganizationCategory="resource" OrgAbbreviation="GeneReviews" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no classification provided</ReviewStatus>
          <GermlineClassification>not provided</GermlineClassification>
          <Citation>
            <ID Source="PubMed">30267299</ID>
          </Citation>
          <Comment>High prevalence in Chinese population; associated with GM1 infantile and late-infantile form</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.4:c.495_497delTCT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268271" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10303272</SubmissionName>
          <SubmissionName>SUB11808016</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2720781" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2020-07-16">
        <ClinVarSubmissionID localKey="2677092|MedGen:C0086652;C0085131" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001385956" DateUpdated="2024-02-28" DateCreated="2020-07-16" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20920281</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30267299</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20920281</ID>
          </Citation>
          <Comment>This variant, c.495_497del, results in the deletion of 1 amino acid(s) of the GLB1 protein (p.Leu166del), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (rs754077128, gnomAD 0.06%). This variant has been observed in individual(s) with GM1-gangliosidosis (PMID: 20920281, 30267299). ClinVar contains an entry for this variant (Variation ID: 684406). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this variant affects GLB1 function (PMID: 20920281). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000003.11:g.33107010_33107012del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0086652" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0085131" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14224806</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1934353" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001336" MappingRef="HP">
        <MedGen CUI="C0027066" Name="Myoclonus" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1934353" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001249" MappingRef="HP">
        <MedGen CUI="C3714756" Name="Intellectual disability" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2720781" TraitType="Disease" MappingType="XRef" MappingValue="C0085131" MappingRef="MedGen">
        <MedGen CUI="C0085131" Name="GM1 gangliosidosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2720781" TraitType="Disease" MappingType="XRef" MappingValue="C0086652" MappingRef="MedGen">
        <MedGen CUI="C0086652" Name="Mucopolysaccharidosis, MPS-IV-B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3562296" TraitType="Disease" MappingType="XRef" MappingValue="C0268271" MappingRef="MedGen">
        <MedGen CUI="C0268271" Name="Infantile GM1 gangliosidosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1934353" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001290" MappingRef="HP">
        <MedGen CUI="C1858120" Name="Generalized hypotonia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1934353" TraitType="Disease" MappingType="XRef" MappingValue="230600" MappingRef="OMIM">
        <MedGen CUI="C0268272" Name="GM1 gangliosidosis type 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1934353" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001250" MappingRef="HP">
        <MedGen CUI="C0036572" Name="Seizure" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

